Clinical Trials Directory

Trials / Unknown

UnknownNCT03899415

TCR-Redirected T Cells Therapy in Patient With HBV Related HCC

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
Beijing 302 Hospital · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This is a single center. single arm, open-label study to determine the safety and clinical benefit of TCR-redirected T cell therapy in patient with HBV related HCC post hepatectomy or radiofrequency ablation.

Conditions

Interventions

TypeNameDescription
BIOLOGICALTCR redirected T cellsHBV antigen specific TCR redirected T cell Infusions. Subjects will receive 1x10\^4 - 5x10\^6 TCR redirected T cells by IV infusion.

Timeline

Start date
2019-04-20
Primary completion
2022-06-01
Completion
2024-06-01
First posted
2019-04-02
Last updated
2019-04-10

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03899415. Inclusion in this directory is not an endorsement.